Covering topics such as mobility equipment and the role of physical therapy, a new, free, online CureDuchenne course seeks…
Mary Chapman
Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Mary Chapman
Entrada Therapeutics has awarded $25,000 grants to three U.S. nonprofits to aid in their efforts to combat healthcare disparities…
A 5-year-old boy has received an infusion of Elevidys, the recently approved gene therapy for Duchenne muscular dystrophy (DMD),…
Thousands of retailers across the U.S. are helping the Muscular Dystrophy Association (MDA) kick off MDA Shamrocks, its…
CITGO raised $2.3 million this year to help advance research, improve patient care, and bolster advocacy efforts for the…
Parent Project Muscular Dystrophy (PPMD) and Duchenne UK will jointly award up to $1 million to two research…
The Muscular Dystrophy Association (MDA) will host the MDA Tribute Awards Oct. 27 in Boston to honor four people who…
The beginning of a new college football season also means it’s time for Coach to Cure MD (CTCMD) —…
Note: This story was updated Aug. 31, 2022, to clarify that MDA Advocate Madison Lawson will throw out the…
Defeat Duchenne Canada is investing $1.14 million in three research projects aimed at providing better treatments for Duchenne…